Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Korsana Biosciences completes a private placement closing, raising $380 million led by Fairmount and Venrock Healthcare Capital Partners to fund operations into 2029.

RECENTLY ACQUIREDSep 08, 2026•about 3 hours ago

Amount Raised

$380 Million

Round Type

Post-IPO Equity

WalthamBiotechnologyHealth CareTherapeutics

Investors

Spruce Street CapitalKalehua CapitalSanofi VenturesSr OneJ.P. Morgan Life Sciences Private CapitalForesite CapitalJanus Henderson InvestorsVivo CapitalRtw InvestmentsRa Capital ManagementCommodore CapitalWellington ManagementForbionTcgxGeneral AtlanticVenrock Healthcare Capital PartnersFairmount

Description

Korsana Biosciences announced the completion of a $380 million private financing from new and existing investors before its merger with Cyclerion Therapeutics. This funding is expected to support multiple clinical milestones for KRSA-028 and ensure financial stability into 2029. Shares will begin trading on Nasdaq under the ticker symbol “KRSA” on September 9, 2026.

Company Information

Company

Korsana Biosciences

Location

Waltham, Massachusetts, United States

About

Korsana Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company leverages its proprietary THETA™ therapeutic targeting platform to improve drug delivery and efficacy. Founded in 2024, Korsana aims to elevate patient care by creating potentially best-in-class therapeutics. The company's lead program, KRSA-028, targets amyloid beta and demonstrates strong preclinical data.

Don't miss Korsana Biosciences's next move

Get an email the moment Korsana Biosciences raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
1 contact
Verified contactsJade M., Senior Talent Partner for NA & EMEA
Predictive Intelligence
Strategic

ML-powered predictions for Korsana Biosciences's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Korsana Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.